1 (tie), A Lim Kim, Hyo Joo Kim, Cheyenne Knight, Lydia Ko and Nelly Korda, 1.00%. 6 (tie), Celine Boutier, Ayaka Furue, Jin Young Ko and Patty Tavatanakit, .67%. 10, Hannah Green, .60%. 1 (tie), ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2024 ...

A quirk in the website OpenSecrets has given RFK Jr. a chance to misleadingly portray Sen. Bernie Sanders as receiving big ...

The Biospecimen Management Consortium (BMC), launched in June 2024 to drive sample excellence in clinical research, is pleased to announce significant progress in its mission to revolutionize ...

A Feature on M&A, VC investment licensing and partnerships focusing on novel targets in autoimmune diseases. The global ...

The Phase 1b/2a study will assess the safety of CNP-103 in adults (aged 18-35) and pediatrics (aged 12-17) who have Stage III or newly diagnosed (within the last 6 months) T1D as well as C-peptide ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX), a $15.4 billion biopharmaceutical company, has reported a recent insider transaction. According to a filing with the Securities and Exchange Commission, ...

In February 2024, the government slashed GST (Goods and Services Tax) from three major cancer drugs: Trastuzumab Deruxtecan, ...

Roche, Novartis, Johnson & Johnson Innovative Medicine, Takeda, SHL Medical, Nestlé, Lindt & Sprüngli, Givaudan, Schneider Electric, Schindler, Endress+Hauser Flowtec, VAT Group and SFS Group. They ...

The global enzyme replacement therapy market size was valued at USD 10.12 billion in 2024 and is projected to grow from USD 11.35 billion in 2025 to reach USD 21.29 billion by 2033, exhibiting a CAGR ...

Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding ...